Company intelligence / Profile preview

Anexa Biomedical

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Anexa Biomedical is a San Diego-based biotechnology company dedicated to developing oral small molecule therapies for metabolic diseases. The company's primary focus is on creating potent, selective, and orally bioavailable GLP-1 receptor agonists to treat conditions such as Type 2 diabetes and obesity. Their lead candidate, ANX-101, is designed to offer a more accessible and patient-friendly alternative to current injectable GLP-1 therapies. By utilizing advanced medicinal chemistry, Anexa aims to address the significant unmet need for effective oral treatments in the metabolic health space. The company is currently progressing its pipeline through preclinical development and IND-enabling studies.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Anexa Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anexa Biomedical.

Explore the full profile